Evidence map›Paper›PMID 32251516›Full record

ArticleCardiovascular research2021

Sustained subcutaneous delivery of secretome of human cardiac stem cells promotes cardiac repair following myocardial infarction.

Andrew R Kompa, David W Greening, Anne M Kong, Paul J McMillan, Haoyun Fang, Ritika Saxena, Raymond C B Wong, Jarmon G Lees, Priyadharshini Sivakumaran, Andrew E Newcomb and 6 more

Erratum issuedOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cardiovascular research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 38 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 1 pooled it
9.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 6 countries.

Andrew R KompaDepartments of Medicine and Surgery, University of Melbourne, Melbourne, VIC, Australia.
David W GreeningMolecular Proteomics, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia.
Anne M KongO'Brien Institute Department, St Vincent's Institute of Medical Research, 9 Princes Street, Fitzroy, VIC 3065, Australia.
Paul J McMillanDepartment of Biochemistry and Molecular Biology, Biological Optical Microscopy Platform, University of Melbourne, Melbourne, VIC, Australia.
Haoyun FangMolecular Proteomics, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia.
Ritika SaxenaO'Brien Institute Department, St Vincent's Institute of Medical Research, 9 Princes Street, Fitzroy, VIC 3065, Australia.
Raymond C B WongDepartments of Medicine and Surgery, University of Melbourne, Melbourne, VIC, Australia.
Jarmon G LeesDepartments of Medicine and Surgery, University of Melbourne, Melbourne, VIC, Australia.
Priyadharshini SivakumaranO'Brien Institute Department, St Vincent's Institute of Medical Research, 9 Princes Street, Fitzroy, VIC 3065, Australia.
Andrew E NewcombDepartment of Cardiothoracic Surgery, St Vincent's Hospital Melbourne, Melbourne, VIC, Australia.
Bakhos A TannousDepartment of Neurology and Pathology, Massachusetts General Hospital, Charlestown, MA, USA.
Cameron KosO'Brien Institute Department & Immunology & Diabetes Unit, St Vincent's Institute of Medical Research, VIC, Australia.
Lina MarianaO'Brien Institute Department & Immunology & Diabetes Unit, St Vincent's Institute of Medical Research, VIC, Australia.
Thomas LoudovarisO'Brien Institute Department & Immunology & Diabetes Unit, St Vincent's Institute of Medical Research, VIC, Australia.
Derek J HausenloyCardiovascular and Metabolic Disorders Program, Duke-National University of Singapore Medical School, Singapore, Singapore.
Shiang Y LimDepartments of Medicine and Surgery, University of Melbourne, Melbourne, VIC, Australia.
O'Brien Institute · AUThe University of Melbourne · AUBaker Heart and Diabetes Institute · AUAsia University · TWDeakin University · AUHarvard University · USSt Vincent's Hospital Melbourne · AU

Funding

British Heart Foundation CS/14/3/31002British Heart Foundation PG/14//30/307
6 · The paper itself

Abstract

aimsTo establish pre-clinical proof of concept that sustained subcutaneous delivery of the secretome of human cardiac stem cells (CSCs) can be achieved in vivo to produce significant cardioreparative outcomes in the setting of myocardial infarction. METHODS AND

resultsRats were subjected to permanent ligation of left anterior descending coronary artery and randomized to receive subcutaneous implantation of TheraCyte devices containing either culture media as control or 1 × 106 human W8B2+ CSCs, immediately following myocardial ischaemia. At 4 weeks following myocardial infarction, rats treated with W8B2+ CSCs encapsulated within the TheraCyte device showed preserved left ventricular ejection fraction. The preservation of cardiac function was accompanied by reduced fibrotic scar tissue, interstitial fibrosis, cardiomyocyte hypertrophy, as well as increased myocardial vascular density. Histological analysis of the TheraCyte devices harvested at 4 weeks post-implantation demonstrated survival of human W8B2+ CSCs within the devices, and the outer membrane was highly vascularized by host blood vessels. Using CSCs expressing plasma membrane reporters, extracellular vesicles of W8B2+ CSCs were found to be transferred to the heart and other organs at 4 weeks post-implantation. Furthermore, mass spectrometry-based proteomic profiling of extracellular vesicles of W8B2+ CSCs identified proteins implicated in inflammation, immunoregulation, cell survival, angiogenesis, as well as tissue remodelling and fibrosis that could mediate the cardioreparative effects of secretome of human W8B2+ CSCs.

conclusionsSubcutaneous implantation of TheraCyte devices encapsulating human W8B2+ CSCs attenuated adverse cardiac remodelling and preserved cardiac function following myocardial infarction. The TheraCyte device can be employed to deliver stem cells in a minimally invasive manner for effective secretome-based cardiac therapy.

Indexed as

ProteomeRegenerationSecretomeStem Cell TransplantationAnimalsAntigens, SurfaceCell ProliferationCells, CulturedCell SurvivalCulture Media, ConditionedDisease Models, AnimalFibrosisHumansMaleMyocardial InfarctionMyocardiumAntigens, SurfaceCulture Media, ConditionedProteomeW8B2 protein, humanCardiac remodellingCardiac stem cellsHeart failureMyocardial infarctionSecretomeTheraCyte

Identifiers

PMID32251516
PMCPMC7898942
OpenAlexW3014228631

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.